Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Mu-opiate Receptor Engagement on Microbial Translocation and Residual Immune Activation in HIV-infected, ART Suppressed Opioid Use Disorder Patients Initiating Medication-assisted Treatment

NCT04480554 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT04480554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Mu-opiate Receptor Engagement on Microbial Translocation and Residual Immune Activation in HIV-infected, ART Suppressed Opioid Use Disorder Patients Initiating Medication-assisted Treatment
Lead sponsor
University of Pennsylvania
Phase
Phase 2
Overall status
Terminated
Start date
January 30, 2023
Completion date
June 30, 2025
Enrollment
78 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

antiretroviral treatment, buprenorphine, hiv-1-infection, immune activation, inflammation, methadone, naltrexone, opioid-use disorder